This article was originally published in The Gray Sheet
New drug application for the firm's 13C urea-based solution included in the Pylori-Chek test kit is undergoing FDA review despite a four-year exclusivity clause granted by FDA to Meretek for its Pranactin combination device/drug system for detection of H.pylori infection in the digestive system, Alimenterics says. On March 13, Meretek filed a petition with FDA requesting a stay of approval of all pending NDAs for 13C urea-based H.pylori tests because it had gained exclusivity from the agency. In an April 7 response to the petition, Alimenterics asserts that the Pylori-Chek is not subject to the exclusivity clause "because the NDA submitted by Alimenterics was a 'full' NDA." Meretek's Sept. 17 Pranactin approval was supported by an abbreviated NDA, Alimenterics explains. In addition to the 13C urea-solution, the Pylori-Chek consists of the 510(k)-cleared LARA non-radioactive carbon urea breath test and a breath collector device. "The Gray Sheet" (March 23, In Brief) incorrectly stated that the LARA breath test is a radioactive carbon urea test
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.